We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDP.L Regulatory News (IDP)

  • There is currently no data for IDP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Completion of Placing

6 Oct 2017 09:55

RNS Number : 9335S
InnovaDerma PLC
06 October 2017
 

LEI: 213800WRAP6W8VDL6B38

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

6 October 2017

InnovaDerma plc

Completion of Placing

 

InnovaDerma plc ("InnovaDerma", the "Company" or, together with its subsidiary undertakings, the "Group") is pleased to announce that, further to the announcement made earlier today (the "Placing Announcement") an aggregate of 1.6 million new ordinary shares of €0.10 each ("Ordinary Shares") in the capital of the Company (the "Placing Shares") have been successfully placed by finnCap Limited ("finnCap") at a price of 276 pence per Placing Share (the "Placing Price") to raise approximately £4.4 million (before expenses) (the "Placing").

Capitalised terms used in this announcement (this "Announcement") have the meanings given to them in the Placing Announcement, unless the context provides otherwise.

The Placing and settlement

The Placing Shares, when issued, will represent approximately 12.7 per cent. of the existing issued share capital of the Company and the Placing Price represents a discount of approximately 14 per cent. to the closing mid-market price of 320 pence per Ordinary Share on 5 October 2017, being the latest practicable date prior to the publication of this Announcement

The Placing Shares, when issued, will be fully paid and will rank pari passu in all respects with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue.

Application will be made for the Placing Shares to be admitted to listing on the standard listing segment of the Official List of the Financial Conduct Authority (the "FCA") and to be admitted to trading on the main market for listed securities of London Stock Exchange plc, (together "Admission").

Settlement for the Placing Shares and Admission is expected to take place on or before 8.00 a.m. on 12 October 2017. The Placing is conditional upon, among other things, upon Admission becoming effective and the Placing Agreement not being terminated in accordance with its terms.

Total voting rights

Following Admission, the Company will have a total of 14,228,405 Ordinary Shares in issue. With effect from Admission, this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure Guidance and Transparency Rules of the FCA.

 

Haris Chaudhry, Executive Chairman of InnovaDerma, said:

"We are delighted to have broadened our institutional shareholder base in this oversubscribed issue. We now have the additional capital to drive the business forward across a number of territories utilising our proven DTC platform and retail distribution channels.

"We are confident in replicating the success of Skinny Tan™ across the rest of our product portfolio and remain excited about the growth prospects of InnovaDerma."

 

Further enquiries:

InnovaDerma

Haris Chaudhry/Joe Bayer

 

+61 (0)3 9863 8030

finnCap Ltd

Geoff Nash/Giles Rolls/Kate Bannatyne

Alice Lane - Corporate Broking

 

+44 (0)207 220 0500

www.finncap.com

Cardew Group

Shan Shan Willenbrock

David Roach

Joe McGregor

 

+ 44 (0)20 7930 0777

 

About InnovaDerma:

 

InnovaDerma PLC (LSE: IDP) specialises in the research, manufacture and marketing of clinically proven products in life sciences, beauty and personal care products. InnovaDerma has presence in Europe, US, Australasia, Asia and Africa. 

This Announcement should be read in its entirety. In particular, you should read and understand the information provided in the "Important Notices" section of this Announcement.

 

 

IMPORTANT NOTICES

MEMBERS OF THE PUBLIC ARE NOT ELIGIBLE TO TAKE PART IN THE PLACING. THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE TERMS AND CONDITIONS SET OUT HEREIN (TOGETHER, THIS "ANNOUNCEMENT") ARE DIRECTED ONLY AT PERSONS WHOSE ORDINARY ACTIVITIES INVOLVE THEM IN ACQUIRING, HOLDING, MANAGING AND DISPOSING OF INVESTMENTS (AS PRINCIPAL OR AGENT) FOR THE PURPOSES OF THEIR BUSINESS AND WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS AND ARE: (1) IF IN A MEMBER STATE OF THE EUROPEAN ECONOMIC AREA ("EEA"), QUALIFIED INVESTORS AS DEFINED IN ARTICLE 2(1)(e) OF DIRECTIVE 2003/71/EC AS AMENDED, INCLUDING BY THE 2010 PROSPECTUS DIRECTIVE AMENDING DIRECTIVE (DIRECTIVE 2010/73/EC) AND TO THE EXTENT IMPLEMENTED IN THE RELEVANT MEMBER STATE (THE "PROSPECTUS DIRECTIVE"); (2) IF IN THE UNITED KINGDOM, QUALIFIED INVESTORS WHO (A) FALL WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE "ORDER") (INVESTMENT PROFESSIONALS) OR (B) FALL WITHIN ARTICLE 49(2)(a) TO (d) (HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS, ETC.) OF THE ORDER (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS").

THIS ANNOUNCEMENT AND THE INFORMATION IN IT MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS. PERSONS DISTRIBUTING THIS ANNOUNCEMENT MUST SATISFY THEMSELVES THAT IT IS LAWFUL TO DO SO. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS. THIS ANNOUNCEMENT DOES NOT ITSELF CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN INNOVADERMA PLC.

THE PLACING SHARES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR JURISDICTION OF THE UNITED STATES, AND MAY NOT BE OFFERED, SOLD OR TRANSFERRED, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES. THE PLACING SHARES ARE BEING OFFERED AND SOLD ONLY OUTSIDE OF THE UNITED STATES IN "OFFSHORE TRANSACTIONS" WITHIN THE MEANING OF, AND IN ACCORDANCE WITH, REGULATION S UNDER THE SECURITIES ACT AND OTHERWISE IN ACCORDANCE WITH APPLICABLE LAWS. NO PUBLIC OFFERING OF THE PLACING SHARES IS BEING MADE IN THE UNITED STATES OR ELSEWHERE.

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

The distribution of this Announcement and/or the Placing and/or issue of the Placing Shares in certain jurisdictions may be restricted by law. No action has been taken by the Company, finnCap or any of their respective affiliates, agents, directors, officers or employees that would permit an offer of the Placing Shares or possession or distribution of this Announcement or any other offering or publicity material relating to such Placing Shares in any jurisdiction where action for that purpose is required. Persons into whose possession this Announcement comes are required by the Company and finnCap to inform themselves about and to observe any such restrictions.

This Announcement or any part of it does not constitute or form part of any offer to issue or sell, or the solicitation of an offer to acquire, purchase or subscribe for, any securities in the United States (including its territories and possessions, any state of the United States and the District of Columbia (the "United States" or the "US")), Australia, Canada, Japan or the Republic of South Africa or any other jurisdiction in which the same would be unlawful. No public offering of the Placing Shares is being made in any such jurisdiction.

All offers of the Placing Shares will be made pursuant to an exemption under the Prospectus Directive from the requirement to produce a prospectus. In the United Kingdom, this Announcement is being directed solely at persons in circumstances in which section 21(1) of the Financial Services and Markets Act 2000 (as amended) does not apply.

The Placing Shares have not been approved or disapproved by the US Securities and Exchange Commission, any state securities commission or other regulatory authority in the United States, nor have any of the foregoing authorities passed upon or endorsed the merits of the Placing or the accuracy or adequacy of this Announcement. Any representation to the contrary is a criminal offence in the United States. The relevant clearances have not been, nor will they be, obtained from the securities commission of any province or territory of Canada, no prospectus has been lodged with, or registered by, the Australian Securities and Investments Commission or the Japanese Ministry of Finance; the relevant clearances have not been, and will not be, obtained for the South Africa Reserve Bank or any other applicable body in the Republic of South Africa in relation to the Placing Shares and the Placing Shares have not been, nor will they be, registered under or offered in compliance with the securities laws of any state, province or territory of Australia, Canada, Japan or the Republic of South Africa. Accordingly, the Placing Shares may not (unless an exemption under the relevant securities laws is applicable) be offered, sold, resold or delivered, directly or indirectly, in or into Australia, Canada, Japan or the Republic of South Africa or any other jurisdiction outside the United Kingdom.

Persons (including, without limitation, nominees and trustees) who have a contractual right or other legal obligations to forward a copy of this Announcement should seek appropriate advice before taking any action.

By participating in the Placing, each person who is invited to and who chooses to participate in the Placing (a "Placee") by making an oral and legally binding offer to acquire Placing Shares will be deemed to have read and understood this Announcement in its entirety, to be participating, making an offer and acquiring Placing Shares on the terms and conditions contained herein and to be providing the representations, warranties, indemnities, acknowledgements and undertakings contained in the Appendix.

This Announcement may contain and the Company may make verbal statements containing "forward-looking statements" with respect to certain of the Company's plans and its current goals and expectations relating to its future financial condition, performance, strategic initiatives, objectives and results. Forward-looking statements sometimes use words such as "aim", "anticipate", "target", "expect", "estimate", "intend", "plan", "goal", "believe", "seek", "may", "could", "outlook" or other words of similar meaning. By their nature, all forward-looking statements involve risk and uncertainty because they relate to future events and circumstances which are beyond the control of the Company, including amongst other things, United Kingdom domestic and global economic business conditions, market-related risks such as fluctuations in interest rates and exchange rates, the policies and actions of governmental and regulatory authorities, the effect of competition, inflation, deflation, the timing effect and other uncertainties of future acquisitions or combinations within relevant industries, the effect of tax and other legislation and other regulations in the jurisdictions in which the Company and its respective affiliates operate, the effect of volatility in the equity, capital and credit markets on the Company's profitability and ability to access capital and credit, a decline in the Company's credit ratings; the effect of operational risks; and the loss of key personnel. As a result, the actual future financial condition, performance and results of the Company may differ materially from the plans, goals and expectations set forth in any forward-looking statements. Any forward-looking statements made in this Announcement by or on behalf of the Company speak only as of the date they are made. Except as required by applicable law or regulation, the Company expressly disclaims any obligation or undertaking to publish any updates or revisions to any forward-looking statements contained in this Announcement to reflect any changes in the Company's expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based.

finnCap is authorised and regulated by the FCA in the United Kingdom and is acting exclusively for the Company and no one else in connection with the Placing, and finnCap will not be responsible to anyone (including any Placees) other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Placing or any other matters referred to in this Announcement.

No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by finnCap or by any of its affiliates or agents as to, or in relation to, the accuracy or completeness of this Announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed.

No statement in this Announcement is intended to be a profit forecast or estimate, and no statement in this Announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

The price of shares and any income expected from them may go down as well as up and investors may not get back the full amount invested upon disposal of the shares. Past performance is no guide to future performance, and persons needing advice should consult an independent financial adviser.

The Placing Shares to be issued pursuant to the Placing will not be admitted to trading on any stock exchange other than the London Stock Exchange.

Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this Announcement.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEGIBDGGUGBGRL
Date   Source Headline
31st May 20221:57 pmRNSScheme of Arrangement Becomes Effective
27th May 20224:01 pmRNSCourt Sanction of Scheme and Suspension
27th May 202210:21 amRNSForm 8.5 (EPT/RI)
25th May 202211:10 amRNSForm 8.5 (EPT/RI)
24th May 202211:48 amRNSForm 8.5 (EPT/RI)
23rd May 202211:49 amRNSForm 8.5 (EPT/RI)
19th May 20223:29 pmRNSResults of Court Meeting and General Meeting
19th May 20229:47 amRNSForm 8.5 (EPT/RI)
16th May 202210:35 amRNSForm 8.5 (EPT/RI)
12th May 202210:13 amRNSForm 8.5 (EPT/RI)
10th May 20229:05 amRNSForm 8.5 (EPT/RI)
9th May 202211:45 amRNSForm 8.5 (EPT/RI)
5th May 202210:00 amRNSScheme Timetable
5th May 20229:04 amRNSForm 8.5 (EPT/RI)
4th May 20229:51 amRNSForm 8.5 (EPT/RI)
3rd May 202210:48 amRNSForm 8.3 - InnovaDerma plc
3rd May 202210:29 amRNSForm 8.5 (EPT/RI)
27th Apr 202211:06 amRNSForm 8.5 (EPT/RI)
25th Apr 20221:31 pmRNSForm 8.3 - InnovaDerma PLC
25th Apr 202212:35 pmRNSPublication of Circular/Notice of General Meeting
25th Apr 202212:30 pmRNSPosting of Scheme Document & IMC Presentation
21st Apr 20221:00 pmRNSForm 8.3 - InnovaDerma PLC
20th Apr 202212:07 pmRNSForm 8.5 (EPT/RI) - InnovaDerma PLC
14th Apr 20229:34 amRNSForm 8.5 (EPT/RI) - InnovaDerma PLC
13th Apr 20226:06 pmRNSForm 8.3 - Innovaderma PLC
13th Apr 20224:30 pmRNSForm 8 (OPD) - InnovaDerma plc
13th Apr 20224:03 pmRNSForm 8.3 - Offeree - InnovaDerma PLC
13th Apr 202211:40 amRNSForm 8.3 - InnovaDerma PLC
13th Apr 20228:47 amRNSForm 8.5 (EPT/RI) - InnovaDerma PLC
13th Apr 20227:00 amRNSForm 8.3 - InnovaDerma PLC
12th Apr 202212:31 pmRNSForm 8.3 - InnovaDerma plc
11th Apr 20226:14 pmRNSForm 8 (OPD) InnovaDerma PLC
8th Apr 20223:00 pmRNSForm 8 (OPD) - InnovaDerma plc
8th Apr 202210:33 amRNSForm 8.5 (EPT/RI)
7th Apr 20229:51 amRNSForm 8.5 (EPT/RI)
6th Apr 202211:03 amRNSForm 8.5 (EPT/RI)
5th Apr 20221:01 pmRNSForm 8.3 - Innovaderma PLC
5th Apr 202211:25 amRNSForm 8.3 - InnovaDerma PLC
4th Apr 202211:16 amRNSForm 8.5 (EPT/RI)
1st Apr 20225:32 pmRNSForm 8.3 - Innovaderma PLC
1st Apr 202211:56 amRNSForm 8.5 (EPT/RI)
1st Apr 202211:00 amRNSForm 8 (DD) - InnovaDerma PLC
31st Mar 20224:44 pmRNSForm 8.3 - Innovaderma Plc
31st Mar 20224:41 pmRNSSecond Price Monitoring Extn
31st Mar 20224:36 pmRNSPrice Monitoring Extension
31st Mar 20222:05 pmRNSSecond Price Monitoring Extn
31st Mar 20222:00 pmRNSPrice Monitoring Extension
31st Mar 20227:01 amRNSRecommended Merger with InnovaDerma Plc
31st Mar 20227:00 amRNSInterim Results
27th Jan 20224:10 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.